New cutting-edge software developed in Melbourne can help uncover how the most common heart tumour in children forms and ...

New President Pledges Stronger Integration and Collaboration Across Chicago's Health System ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Novo Nordisk (NVO) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of ...